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The host eIF4F translation initiation complex plays a critical role the translation of capped mRNAs. Although human cytomega-
lovirus (HCMV) infection increases the abundance and activity of the host eIF4F complex, the requirement for eIF4F compo-
nents in HCMV replication and mRNA translation has not been directly tested. In this study, we found that decreasing the abun-
dance or activity of eIF4F from the start of infection inhibits HCMV replication. However, as infection progresses, viral mRNA
translation and replication becomes increasingly resistant to eIF4F inhibition. During the late stage of infection the association
of representative immediate-early, early, and late mRNAs with polysomes was not affected by eIF4F disruption. In contrast,
eIF4F inhibition decreased the translation of representative host eIF4F-dependent mRNAs during the late stage of infection. A
global analysis of the translation efficiency of HCMV mRNAs during the late stage of infection found that eIF4F disruption had a
minimal impact on the association of HCMV mRNAs with polysomes but significantly diminished the translation efficiency of
eIF4F-dependent host transcripts. Together, our data show that the translation of host eIF4F-dependent mRNAs remains depen-
dent on eIF4F activity during HCMV infection. However, during the late stage of infection the translation efficiency of viral mR-
NAs does not correlate with the abundance or activity of the host eIF4F complex.
As obligate intracellular parasites, viruses are reliant on cellularprocesses for their replication. At a minimum, viruses require
host ribosomes to synthesize viral proteins. While host cells have
evolved to limit mRNA translation during infection, viruses have
evolved to limit host control of protein synthesis in infected cells
to maximize viral protein expression. Thus, the interaction of viral
mRNAs with the host translation machinery represents a funda-
mental aspect of the host-pathogen interface.
The recruitment of a ribosome to host mRNAs occurs through
an ordered assembly of translation factors on the 5= terminus of
the message. In particular, the eIF4F complex is a critical host
translation initiation complex required for the efficient recruit-
ment of ribosomes to mRNAs containing a 7-methylguanosine
cap (m7G cap) on their 5= terminal nucleotide (1–3). Most cellular
messages are capped (4), and therefore the eIF4F complex is
thought to be required for the translation of the majority of cellu-
lar mRNAs. The three components of eIF4F each play specialized
roles in translation initiation (5). The eIF4E protein nucleates the
assembly of the eIF4F complex by binding to the m7G mRNA cap
(6). eIF4E recruits the eIF4G scaffold protein, which in turn re-
cruits the eIF4A RNA helicase to complete the eIF4F complex. The
eIF4A helicase stimulates translation initiation by resolving
secondary structures in the 5= untranslated region (5=UTR) of
mRNAs, thereby facilitating ribosomal scanning to the initiating
codon (7, 8). Recruitment of the eIF4F complex to the m7G cap is
a rate-limiting step in the initiation of mRNA translation, and
reducing the amount of eIF4F complex results in a global decrease
in protein synthesis.
Herpesviruses do not encode obvious homologs of eIF4F sub-
units, and herpesvirus mRNAs are thought to be translated in a
cap-dependent manner, although cap-independent translation
has been described for a limited number of herpesvirus mRNAs
(9–12). This is based in part on studies showing that human cyto-
megalovirus (HCMV) infection induces the accumulation of
eIF4F subunits (13). In addition, HCMV infection activates sig-
naling pathways that stimulate eIF4F complex formation. For ex-
ample, HCMV activates the mTOR kinase (13–16). Active mTOR
facilitates eIF4F complex formation by phosphorylating and
antagonizing the translation repressor 4EBP-1, which prevents
the formation of eIF4F on the mRNA cap (17, 18). HCMV also
stimulates the ERK and MEK kinase cascades, resulting in the
phosphorylation of eIF4E by the Mnk1/2 kinases (13). In sum,
these events ensure that the eIF4F complex remains active during
infection despite the induction of a cellular stress response.
These findings suggest that HCMV infection increases eIF4F
activity to stimulate the translation of viral mRNAs. However,
several recent studies have suggested a more complicated role for
eIF4F during herpesvirus infection (19). For example, while in-
hibiting the mTOR kinase from the start of HCMV infection dis-
rupts the eIF4F complex and limits virus replication, some HCMV
mRNAs continue to be efficiently translated (16). As infection
progresses, both total protein synthesis and virus replication be-
come increasingly resistant to the effects of mTOR inhibitors, de-
spite significant disruption of the eIF4F complex (19). This sug-
gests that mTOR has additional eIF4F-independent roles in virus
Received 4 September 2013 Accepted 1 November 2013
Published ahead of print 6 November 2013
Address correspondence to Nathaniel J. Moorman, nmoorman@med.unc.edu.
* Present address: Gabe De Leon, Preston A. Wells, Jr., Center for Brain Tumor
Therapy, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA;
Duane Mitchell, Preston A. Wells, Jr., Center for Brain Tumor Therapy, McKnight
Brain Institute, University of Florida, Gainesville, Florida, USA.
E.L. and B.Z. contributed equally to this article.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/JVI.02321-13.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.02321-13
February 2014 Volume 88 Number 3 Journal of Virology p. 1473–1483 jvi.asm.org 1473
replication, perhaps in the metabolic remodeling of HCMV-in-
fected cells (20). These data suggest that the eIF4F complex may
not be required for viral mRNA translation during the later stages
of infection. However, the requirement for eIF4F activity for
HCMV protein synthesis has not been directly assessed.
In this study, we measured the impact of eIF4F inhibition on
host and viral mRNA translation during HCMV infection. Inhib-
iting eIF4F at the time of infection limits progression through the
viral lytic cycle despite the efficient expression of HCMV imme-
diate-early proteins. After the onset of viral DNA replication both
viral protein synthesis and replication became increasingly resis-
tant to eIF4F inhibition. We found that disrupting the eIF4F com-
plex inhibited the association of host mRNAs with polysomes and
consequently limited host protein synthesis during HCMV infec-
tion. In contrast, eIF4F inhibition had a minimal effect on the
synthesis of representative viral proteins from each kinetic class
and did not affect the association of the corresponding viral
mRNAs with polysomes. Global analysis of the translation effi-
ciency of viral transcripts revealed robust translation of HCMV
mRNAs despite a significant reduction in eIF4F abundance. Our
data suggest a differential requirement for eIF4F activity for the
translation of host and viral mRNAs during the late stage of infec-
tion. Although host mRNAs continue to require eIF4F for their
translation during infection, the association of viral mRNAs with
ribosomes is insensitive to changes in eIF4F abundance or activity.
MATERIALS AND METHODS
Cells, viruses, and inhibitors. Primary human foreskin fibroblasts
(HFFs) were passaged in Dulbecco modified Eagle medium (DMEM;
Sigma) containing 10% newborn calf serum and used between passages 7
and 14. Unless otherwise indicated, the cells were seeded at confluence
and then serum starved for 48 h prior to infection. HCMV infections were
performed with the BADinGFP strain (ADGFP) (21), which contains the
green fluorescent protein (GFP) open reading frame under the control of
the simian virus 40 promoter inserted in the nonessential UL21.5 locus.
HCMV infections were performed at a multiplicity of infection (MOI) of
three in serum-free medium unless otherwise noted. Cell-free HCMV was
titered by the 50% tissue culture infectious dose (TCID50) method on
primary human fibroblasts. The eIF4AI/II inhibitor hippuristanol (22)
was generously provided by Jerry Pelletier (McGill University). Cyclohex-
imide, actinomycin D, and phosphonoacetic acid (PAA), all obtained
from Sigma, were used at final concentrations of 100, 5, and 200 g/ml,
respectively. Unless otherwise noted, Torin1 (Tocris) was used at a final
concentration of 250 nM.
Western blot analysis of host and viral proteins. Cell pellets were
lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl
[pH 7.4], 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM
EDTA) containing protease inhibitors (Complete EDTA-free; Roche).
Cells were incubated on ice in RIPA buffer for 15 min and then cleared of
debris by centrifugation for 10 min at 14,000  g. The protein concentra-
tion of each sample was determined using the Bradford reagent. Equal
amounts of protein from each sample were resolved on 10% polyacryl-
amide gels, transferred to nitrocellulose membranes (Whatman), and
then blocked for at least 1 h in Tris-buffered saline containing 0.05%
Tween 20 (TBS-T) and 5% nonfat milk. Primary mouse monoclonal an-
tibodies were diluted in TBS-T containing 1% bovine serum albumin
(BSA) and incubated with the membrane for 1 h at room temperature.
Rabbit polyclonal antibodies were incubated overnight at 4°C in TBS-T
containing 5% BSA. After being washed with TBS-T, blots were incubated
with horseradish peroxidase-conjugated secondary antibodies for 1 h at
room temperature. The blots were again washed in TBS-T, and proteins
were visualized by treatment with enhanced chemiluminescence reagent
(Amersham or Advansta) and exposure to film. The following antibodies
and dilutions were used in the present study: IE1 (1:100), UL44 (1:100),
pp28 (1:100), tubulin (Sigma, 1:5,000), rpS6 (1:1,000), phospho-rpS6 (1:
2,000), eIF4A (1:1,000), eIF4E (1:1,000), eIF4G (1:1,000), 4EBP1 (1:
1,000) from Cell Signaling, hsp90 (Enzo,1:1,000), and RACK1 (Santa
Cruz, 1:1,000).
Metabolic labeling of HFFs. At the indicated times postinfection, the
medium was removed and replaced with serum-free DMEM lacking me-
thionine and cysteine (Sigma). After a 15-min incubation, 125 Ci of
35S-labeled methionine-cysteine (EasyTag Express protein labeling mix;
Perkin-Elmer) was added directly to each well. In experiments measuring
the total protein synthesis the cells were labeled for 30 min. Cells were
labeled for 1 h where the synthesis of specific proteins was measured. The
medium was then removed, and the cells were washed three times with
ice-cold phosphate-buffered saline (PBS). Cells were pelleted and stored
at 80°C until analyzed. Where the effect of inhibitors was tested, the
inhibitors were included in both the methionine-cysteine-free incubation
and labeling periods.
Analysis of total protein synthesis. 35S-labeled cells were lysed in 100
l of RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% sodium deoxycholate) containing protease in-
hibitors (complete EDTA-free protease inhibitor; Roche). The protein
concentration of the lysate was then determined by the Bradford assay.
Fifteen microliters of cell extract was mixed with 0.1 ml of 1 mg of BSA/ml
containing 0.02% (wt/vol) sodium azide (NaN3). One milliliter of 20%
trichloroacetic acid (TCA) was added to the sample, and the mixture was
vortexed and incubated on ice for 30 min. The precipitate was vacuum
filtered onto 2.5-cm glass microfiber filters (Whatman). The filters were
washed twice with 20% TCA, once with 100% ethanol, and allowed to air
dry for 30 min. The amount of radioactivity retained on the filters was
measured using a scintillation counter. The amount of precipitated radio-
activity in each sample was normalized to the total amount of protein in
the sample. In some cases, metabolically labeled proteins were visualized
by resolving 10 g of protein on SDS–10% PAGE gels. Gels were dried for
1 h and then exposed to film to visualize radiolabeled proteins.
Quantification of viral DNA. HCMV DNA accumulation was mea-
sured essentially as described previously (23). Briefly, HFFs were seeded at
confluence in six well plates, and then serum starved for 48 h prior to
infection. The cells were infected at an MOI of 0.05, and inhibitors were
added after removal of the inoculum. Control infected cells were treated
with dimethyl sulfoxide vehicle. At 96 h postinfection (hpi), the cells were
scraped from the dishes, pelleted, and frozen at 80°C. Frozen cell pellets
were resuspended in 100 l of lysis buffer (RIPA buffer) and digested
overnight with proteinase K (10 mg/ml). The lysates were extracted with
phenol-chloroform, and the DNA was precipitated with isopropanol. The
DNA pellet was resuspended in distilled water and quantified using a
NanoDrop spectrometer. Portions (500 ng) of DNA were analyzed by
quantitative real-time PCR (qPCR) exactly as described previously (16)
using primers specific for the HCMV major immediate-early promoter
(MIEP) (see Table S1 in the supplemental material). The number of
HCMV genomes in each sample was determined by comparing the results
to a series of DNA standards containing from 108 to 101 HCMV genomes.
To control for variations in pipetting, the results were normalized to the
total amount of DNA in each sample by qPCR using primers specific for
GAPDH (glyceraldehyde-3-phosphate dehydrogenase).
Polysome isolation. Polysomes were isolated by centrifugation
through 10 to 50% linear sucrose gradients. Linear sucrose gradients were
prepared by pouring sucrose step gradients and allowing them to equili-
brate overnight at 4°C. Step gradients consisted of 10, 20, 30, 40, and 50%
sucrose steps, each prepared in polysome gradient buffer (20 mM Tris-
HCl [pH 7.4], 140 mM KCl, 5 mM MgCl2) containing 100 g of cyclo-
heximide/ml. Confluent serum-starved fibroblasts were infected at an
MOI of 3 in serum-free media. At 72 h postinfection, the cells were treated
with Torin1 or left untreated. After another 16 h, the cells were incubated
in serum-free media containing cycloheximide for 10 min at 37°C. The
cells were washed three times in PBS containing cycloheximide and
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scraped from the dishes and pelleted (5 min at 3,000  g). The cell pellets
were resuspended in polysome gradient buffer containing cycloheximide,
1 mM dithiothreitol, and 1% Triton X-100. The cells were swollen on ice
for 10 min and then disrupted by five passes through a 27-gauge needle.
Nuclei were removed by centrifugation for 5 min at 2,500  g. The result-
ing supernatant was cleared of insoluble debris by centrifugation for 10
min at 13,000  g. The resulting supernatant was layered onto the sucrose
gradients and spun in an ultracentrifuge (Becton-Dickinson) for 2 h at
32,500 rpm in an SW41 swinging bucket rotor. The centrifuge brake was
disabled to avoid disrupting the gradients during deceleration. After cen-
trifugation, the gradients were manually fractionated from the top into 14
750-l fractions. The bottom fraction of the gradient (fraction 15) con-
taining any pelleted debris, was discarded. RNA was extracted from one
third of each gradient fraction and resolved on 2% nondenaturing agarose
gels to visualize rRNA. We routinely monitored the efficiency of fraction-
ation by performing Western blots for the nuclear protein lamin A/C and
cytoplasmic protein tubulin (data not shown). In each experiment, the
efficiency of mTOR inhibition was measured by performing Western
blots on whole-cell extracts using antibodies specific for either phosphor-
ylated or total ribosomal protein S6 (rpS6).
Quantification of viral mRNA abundance. The abundance of specific
mRNAs in total cellular RNA was quantified by reverse transcriptase real-
time PCR (qRT-PCR) as previously described (24). Briefly, frozen cell pellets
were resuspended in TRIzol (Invitrogen). The mixture was extracted with
chloroform, and the RNA was precipitated with isopropanol. RNA pellets
were resuspended in RNase-free water, and RNA was quantified using a
NanoDrop spectrometer. Two micrograms of RNA was reverse transcribed
with a high-capacity reverse transcription kit (ABI) using random hexamers
as primers. Two microliters of the resulting cDNA was mixed with gene-
specific primers and SYBR green master mix and amplified in a Roche Light-
Cycler 4800 using the following cycling parameters: 95°C for 5 min and then
40 cycles consisting of 95°C for 30 s and 60°C for 30 s. The amount of viral
transcript in each sample was determined by using the CT method, with
GAPDH as the reference sample.
To quantify the abundance of mRNAs in sucrose gradient fractions,
RNA was extracted from one-third of each gradient fraction. An equal
volume of RNA from each fraction was reverse transcribed, and an equal
volume of the cDNA reaction was analyzed by real-time PCR analysis as
described above. The abundance of each transcript was determined by
comparing the threshold values for each sample to a standard curve spe-
cific for each primer set. For viral transcripts, the standard curve consisted
of a range of HCMV BAC DNA concentrations ranging from 108 to 101
copies. For host transcripts, the PCR product of each primer pair was
cloned into the pGEM-T vector. The threshold values obtained from a
series of DNA standards containing from 108 to 101 copies was used to
determine the abundance of each transcript in each fraction. The total
amount of each transcript in the gradient was determined by summing the
copy number of the transcript across all fractions. The percentage of the
mRNA present in each fraction of the gradient was then graphed to dem-
onstrate the relative distribution of a transcript across the gradient.
Primer sequences for both host and viral genes are listed in Table S1 in the
supplemental material.
shRNA-mediated depletion of host mRNAs. Lentivirus shRNA ex-
pression constructs targeting eIF4A1 were obtained from the University
of North Carolina Lentivirus Core Facility. Lentivirus stocks were pre-
pared by transfecting 293T cells with lentivirus shRNA construct together
with packaging vectors. Cell-free supernatants were harvested 3 days post-
transfection and filtered through a 0.45-m-pore-size filter. One day
prior to transduction, the HFFs were seeded at confluence into six-well
plates. The cells were transduced with lentivirus overnight in the presence
of 5 g of Polybrene/ml. The next morning, the medium was removed,
and the cells were washed with PBS. Serum-free media was then added to
the wells, and the cells were incubated for an additional 48 h prior to
infection with HCMV as described above.
Analysis of cap structures on viral mRNAs. Polysome-associated
mRNAs were isolated from untreated of Torin1-treated, infected cells.
The RNAs were treated with calf-intestinal phosphatase to remove 5=
phosphates from uncapped RNAs and then treated with TAP to remove
the m7G cap. An RNA oligonucleotide was then ligated to the decapped
mRNA. All reagents were from an RLM-RACE kit (Ambion) essentially as
described in the product manual. The RNA was then reverse transcribed
and PCR amplified using primers specific for the viral sequence and the
RNA oligonucleotide. The omission of TAP should prevent ligation of the
RNA oligonucleotide if the mRNA contains a 5= m7G cap, and therefore
amplification of the cDNA would be prevented. In some samples the TAP
digestion step was omitted to test for the presence of the mRNA cap
structure.
Microarray analysis of translation efficiency. Polysome-associated
and total RNA were isolated as described above. Sample quantity and
quality was verified by using an Agilent 2100 bioanalyzer. Total RNA and
polysome RNA was labeled with Cy3 or Cy5, respectively, using the Agi-
lent LIQA two-color labeling protocol according to the manufacturer’s
instructions. Samples were hybridized to a custom microarray developed
on the Agilent Human GE 4x44K v2 Microarray platform. In addition to
probes specific for the whole human genome, the microarray contained
oligonucleotide probes specific for all of the annotated genes of the WT
Merlin HCMV genome (NCBI accession no. NC_006273). Microarray
hybridization, washing, and signal intensity analysis were performed ac-
cording to the manufacturer’s directions. The data were collected using
the Feature Extraction software. The data analysis was carried out using
Partek Genomics Suite software. Only probes showing positive signal in
all samples were subjected to further analysis. To determine the transla-
tion efficiency of a given gene, the signal intensity from the polysomes
RNA was divided by that in the total RNA. To determine the relative
change in translation efficiency in the presence of Torin1, the translation
efficiency of mRNA in Torin1-treated cells was divided by that in un-
treated cells. Statistically significant changes in translation efficiency in the
presence of Torin1 were calculated using a Student paired two-tailed t test.
The experiment was performed three times using RNAs derived from
three independent experiments.
RESULTS
To test the requirement for eIF4F activity for the translation of
viral mRNAs, we measured the effect of a specific inhibitor of the
eIF4A RNA helicase on viral replication and protein synthesis.
Hippuristanol is an ATP-competitive inhibitor that binds directly
to the active site of eIF4AI and eIF4AII and inhibits their RNA
helicase activity (22, 25). Importantly, hippuristanol is a specific
inhibitor of eIF4AI and eIF4AII, and it does not affect the activity
of other RNA helicases (25). Therefore, unlike other eIF4F inhib-
itors that target signaling pathways that control eIF4F integrity,
hippuristanol directly targets the enzymatic activity of the eIF4F
complex. Consistent with the requirement of eIF4A activity for
the translation of most cellular mRNAs, hippuristanol inhibits
protein synthesis in mammalian cells (22, 25). We found that 100
nM hippuristanol potently inhibited the total rate of protein syn-
thesis in uninfected cells (Fig. 1A) without affecting cell viability
(Fig. 1B) or mTOR signaling (Fig. 1C). We therefore used hip-
puristanol treatment to determine the requirement for eIF4A ac-
tivity for the translation of viral mRNAs during HCMV infection.
We first determined the effect of hippuristanol on HCMV im-
mediate-early (IE) protein expression. Cells were serum starved
for 48 h and then infected with HCMV and treated with hip-
puristanol at the time the inoculum was removed. Serum starva-
tion was included to better assess the stimulatory effects of HCMV
infection on eIF4F activity and to allow us to compare our results
to previously published studies. The expression of HCMV imme-
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diate-early protein IE1 was then measured by Western blotting at
6 h postinfection. As expected, cycloheximide, an inhibitor of pep-
tide elongation, prevented IE1 protein expression (Fig. 1D). Con-
sistent with our previous studies (16), the mTOR inhibitor Torin1
did not limit IE1 protein expression. Surprisingly, hippuristanol
treatment also had no effect on IE1 protein levels despite limiting
total protein synthesis to a similar degree as cycloheximide. A
potential explanation for this result could be that inhibiting eIF4A
helicase activity resulted in a compensatory increase in IE1 mRNA
transcription. However, qRT-PCR analysis of IE1 mRNA levels
showed that similar amounts of the IE1 mRNA were present in
untreated and hippuristanol-treated cells (Fig. 1E). Since similar
amounts of IE1 mRNA and protein were made when eIF4A was
inhibited, this result demonstrates that inhibiting eIF4A helicase
activity does not decrease the efficiency of IE1 mRNA translation
despite a global reduction in the rate of protein synthesis.
We next determined the effect of inhibiting eIF4A at the time of
infection on the progression of the HCMV lytic cycle. As shown in
Fig. 2A, the IE1 protein was expressed throughout the HCMV lytic
cycle in the presence of hippuristanol. The expression of the
HCMV early protein UL44 (pUL44) was delayed and reduced by
hippuristanol treatment; however, pUL44 continued to increase
in abundance as infection progressed. In contrast, the expression
of pp28 was significantly diminished in hippuristanol treated cells
at all times postinfection. We investigated the defect in pp28 ex-
pression in more detail by determining whether the decrease in
pp28 protein levels was due to decreased transcription or transla-
tion of the pp28 mRNA. Quantitative real-time PCR analysis
found that pp28 mRNA levels were reduced when hippuristanol
was added to the cultures at the time of infection (Fig. 2B). Since
transcription of HCMV late mRNAs is dependent on viral DNA
replication, we hypothesized that the defect in pp28 transcription
might be due to a requirement for eIF4A activity for efficient viral
DNA accumulation. Infected cells were treated with hippuristanol
at the time of infection, and viral DNA was isolated and quantified
by real-time PCR at 96 h postinfection. As a control, we also mea-
sured the level of viral DNA in cells treated with PAA, a well-
described inhibitor of HCMV DNA replication. Hippuristanol
and PAA similarly reduced viral DNA accumulation by approxi-
mately 2 orders of magnitude (Fig. 2C). Therefore, the reduction
in pp28 expression when hippuristanol is added at infection is due
to a requirement for eIF4A activity for viral DNA replication.
Consistent with the effect of hippuristanol on viral DNA accu-
mulation and late gene transcription, hippuristanol potently in-
hibited the production of cell-free progeny virus when added at
the time of infection (Fig. 3A). The effects of hippuristanol were
dose dependent (Fig. 3B) consistent with the specific inhibition of
eIF4A in a nontoxic manner. We used shRNA-mediated depletion
of eIF4A1 as an additional approach to confirm the phenotypes
observed following hippuristanol treatment. Similar to hip-
FIG 1 An HCMV immediate-early protein is efficiently translated in the pres-
ence of an eIF4A inhibitor. (A) HFFs were infected with HCMV (MOI of 3)
and treated with vehicle (NT), Torin1 (T; 250 nM), actinomycin D (ActD; 10
g/ml), cycloheximide (CHX; 100 g/ml), or hippuristanol (HP; 100 nM)
when the inoculum was removed. The rate of incorporation of radiolabeled
amino acids into acid-insoluble protein during the final 30 min of the infection
was measured (n  3). Values are expressed as a percentage of the untreated,
uninfected control. (B) Uninfected HFFs were treated with the indicated con-
centrations of hippuristanol for 5 days. Cell viability was determined by the
LDH assay (n  2). (C) Cells were mock infected (M) or infected and treated
as for panel B. Cells were harvested at 6 h postinfection (hpi), and the levels of
phosphorylated rpS6 and total rpS6 were determined by Western blotting (n 
2). (D) Same as for panel C, except the IE1 and tubulin levels were measured by
Western blotting (n  3). (E) Same as for panel D, except that RNA was
harvested at 6 hpi, and IE1 mRNA abundance was measured by qRT-PCR. The
abundance of IE1 mRNA in untreated cells was set to 1 (n  3).
FIG 2 Hippuristanol inhibits progression through the HCMV lytic cycle. (A) Serum-starved confluent HFFs were infected with HCMV at an MOI of 3. Cells were left
untreated or treated with hippuristanol (HP; 100 nM) when the inoculum was removed. Cells were harvested at 24-h intervals, and viral protein expression was measured
by Western blotting (n  3). (B) Cells were infected and treated as in panel A, and pp28 mRNA abundance was determined by qRT-PCR (n  3). The fold change in pp28
mRNA levels relative to the 24-h time point is shown. Bars: , untreated samples; , HP treated samples. (C) Serum-starved confluent HFFs were infected at an MOI
of 0.05. Hippuristanol (HP; 100 nM) or phosphonoacetic acid (PAA; 200 g/ml) was added at the time of infection. At 96 hpi, viral DNA was quantified by qPCR. The
results were normalized to the abundance of GAPDH DNA in the sample to control for variations in loading (n  3).
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puristanol treatment, the HCMV IE protein IE1 and the early
protein pUL44 were expressed in eIF4A1-depleted cells, although
pUL44 expression was delayed and reduced (Fig. 3C). Limiting
eIF4A1 expression prior to infection also decreased the yield of
cell-free virus by 150-fold (Fig. 3D). Similar results were obtained
using a separate eIF4A-specific shRNA (data not shown). These data
confirm the results obtained in hippuristanol-treated cells and sup-
port the conclusion that eIF4A activity is required at the onset of
infection for progression through the HCMV lytic cycle.
We next performed experiments to address the temporal require-
ment for eIF4A activity in HCMV mRNA translation and virus rep-
lication. Cells were infected with HCMV, and then hippuristanol was
added to the infected cells for a 24-h period beginning at different
times postinfection (e.g., from 24 to 48 h, 48 to 72 h, etc.). For com-
parison, vehicle-treated cells were harvested at the time of hippurista-
nol addition, and at the end of the 24-h treatment period. We first
measured the rate of incorporation of radiolabeled amino acids into
protein in the presence of hippuristanol of different times postinfec-
tion. Hippuristanol inhibited total protein synthesis in both unin-
fected and infected cells by 70% (Fig. 4A). We also visualized pro-
teins made during the final 30 min of the hippuristanol treatment on
acrylamide gels by autoradiography. Interestingly, in HCMV-in-
fected cells a subset of proteins continued to be efficiently synthesized
in the presence of hippuristanol during the later stages of infection
(Fig. 4A). These proteins were only observed in infected cells, suggest-
ing that they were viral proteins.
Using the same treatment protocol, we next evaluated the ef-
fect of hippuristanol on viral protein levels. Adding hippuristanol
at any time following infection did not affect levels of the IE1
protein (Fig. 4B). Levels of the early UL44 protein increased be-
tween 24 and 48 h in the presence of hippuristanol, although to a
lower level than in untreated cells. The addition of hippuristanol
at later times after infection did not affect the levels of pUL44. The
late protein pp28 was first detected at 48 h in untreated cells;
however, pp28 was undetectable in cells treated with hippurista-
nol between 24 and 48 h. Hippuristanol also limited the accumu-
lation of pp28 between 48 and 72 h postinfection. Beyond 72 h,
hippuristanol had minimal effect on the steady-state levels of pp28
protein. As a more direct measure of the rate of viral protein syn-
thesis, we measured the incorporation of radiolabeled amino acids
into specific viral proteins during the final hour of hippuristanol
treatment. Representative immediate-early, early, and late pro-
teins were immunoprecipitated from the labeled cell lysates and
visualized by autoradiography. The results show that the HCMV
IE1 and UL44 proteins were efficiently synthesized in the presence
of hippuristanol (Fig. 4C). Hippuristanol had a modest effect on
the synthesis of the pp28 protein; however, nascent pp28 protein
was clearly detectable. In contrast, cycloheximide completely in-
hibited nascent protein synthesis (Fig. 4C). These results suggest
that viral protein synthesis is largely independent of eIF4A activity
during the late stage of HCMV infection.
We also determined the temporal requirement for eIF4A activ-
ity for the production of HCMV progeny virus. In marked con-
trast to the results obtained when eIF4A was inhibited at the start
of infection, hippuristanol had minimal impact on the accumula-
tion of cell-free virus during the later stages of infection (Fig. 4D).
In control cells the amount of cell-free virus increased by approx-
imately 2 orders of magnitude between 48 and 72 h postinfection.
Hippuristanol treatment had a 	5-fold effect on virus replication
during the same time frame. Virus titers increased an additional
FIG 3 Inhibiting eIF4AI at the time of infection limits HCMV replication. (A) Serum-starved confluent HFFs were infected with HCMV at an MOI of 3. Cells
were left untreated () or treated with 100 nM hippuristanol () at the time of infection. Cell-free virus was quantified by the TCID50 method (n  3). (B) Cells
were infected as described for panel A. The indicated concentrations of hippuristanol were added at the time of infection. The amount of cell-free virus
supernatants at 120 hpi was determined by the TCID50 method (n  2). (C) Cells expressing control () or eIF4AI (
) specific shRNA were infected with HCMV
at an MOI of 3. Viral protein expression was measured as in Fig. 2A (lanes marked with , scrambled shRNA; eIF4AI KD, eIF4AI shRNA; n  3). (D) Same as
in panel C, except the amount of cell-free virus in the supernatant was quantified by the TCID50 assay (n  3). Closed bars, scrambled shRNA; open bars, eIF4AI
shRNA.
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10-fold between 72 and 96 h postinfection in untreated cells. Hip-
puristanol treatment had no negative effect on virus replication
during this time and in fact slightly increased the yield of cell-free
virus. These data show that HCMV replication becomes increas-
ingly resistant to eIF4A inhibition as infection progresses.
As part of the eIF4F complex, the eIF4A helicase resolves sec-
ondary structures in the 5=UTR of mRNAs that might otherwise
impede ribosome scanning (7, 8). A possible explanation for the
translation of viral mRNAs when eIF4A is inhibited could be that
viral mRNAs lack extensive secondary structure in their 5=UTRs
and therefore do not require the eIF4A helicase activity for their
mRNA translation. However, assembly of the eIF4F complex
might still be required to recruit 40S ribosomal subunits to viral
mRNAs, since the eIF4G subunit bridges interactions between
eIF4F and the 43S preinitiation complex. We therefore deter-
mined the impact of eIF4F disruption on HCMV mRNA transla-
tion. We used the mTOR inhibitor Torin1, a specific ATP-com-
petitive inhibitor of mTOR kinase activity, to decrease eIF4F
abundance in infected cells (26). We focused on the late stage of
infection since our data from hippuristanol-treated cells sug-
gested a minimal requirement for eIF4F activity for the synthesis
of viral proteins during this stage of infection. Torin1 treatment
decreased the amount of eIF4G that copurified with m7G-Sephar-
ose while conversely increasing the binding of the translational
repressor 4EBP1 (Fig. 5A), demonstrating that Torin1 disrupted
the eIF4F complex during the late stage of infection. Torin1 also
limited nascent protein synthesis in both infected and uninfected
cells. Similar to the results in hippuristanol-treated cells, the syn-
thesis of a subset of infected cell specific proteins appeared to be
less affected by Torin1 (Fig. 5B). We also found that polysome
formation in infected cells was resistant to the effects of Torin1,
while Torin1 treatment diminished polysomes abundance in un-
infected cells (Fig. 5C). Our results show that a subset of mRNAs
efficiently recruits ribosomes in infected cells despite significant
disruption of the eIF4F complex.
We next determined the effect of eIF4F disruption on the
translation of host mRNAs during the late stage of infection.
Cytoplasmic extracts from control or Torin1-treated infected cells
were resolved through sucrose density gradients to separate ribo-
somal subunits, monosomes, and polysomes. The relative abun-
dance of specific host mRNAs in each gradient fraction was mea-
sured by qRT-PCR. If the recruitment of ribosomes to the mRNA
is dependent on the abundance of eIF4F complex, then Torin1
treatment should result in a shift of mRNAs from the polysomes-
containing fractions to the lighter, monosome-containing frac-
tions of the gradient. Conversely, if ribosomes bind the mRNA
equally as well when eIF4F is disrupted, the distribution of the
mRNA in the gradient should be unaffected by Torin1. Impor-
tantly, this assay only measures the distribution of cytoplasmic
FIG 4 HCMV replication and protein synthesis becomes increasingly resis-
tant to inhibition by hippuristanol as infection progresses. (A) HFFs were left
uninfected (Mock) or infected with HCMV at an MOI of 3. Cultures were
treated with 100 nM hippuristanol for the indicated 24-h period. Nascent
proteins were metabolically labeled during the final 30 min of drug treatment
and visualized by autoradiography (n  3). (B) Cells were infected and treated
as in panel A. Cells were harvested at the indicated times, and viral protein
expression was measured by Western blotting (n  3). (C) Cells were infected
as in panel A. At 80 hpi, the cells were treated with either hippuristanol or
cycloheximide. Nascent proteins were metabolically labeled during the final
hour of the drug treatments, and the indicated viral proteins were immuno-
precipitated from the lysates and visualized by autoradiography (n  2). (D)
HFFs were infected as in panel A. At the indicated times, hippuristanol (HP;
100 nM) was added to the cultures. Cell-free virus present at the end of the
24-h hippuristanol treatment () was quantified by the TCID50 assay. Super-
natants from untreated cultures (NT; ) were harvested, and titers were de-
termined at the indicated times (n  3).
FIG 5 Effect of eIF4F disruption on protein synthesis in HCMV-infected cells during the late stage of infection. (A) At 80 hpi (MOI of 3), the cells were treated
with Torin1 (250 nM) for 16 h or left untreated. The integrity of the eIF4F complex was measured using m7G Sepharose affinity purification. (B) Same as in panel
A, except nascent proteins were metabolically labeled during the final 30 min of Torin1 treatment and visualized by autoradiography (C) Same as for panel A,
except cytoplasmic lysates were resolved through 10 to 50% sucrose gradients to separate ribosomal subunits, monosomes, and polysomes. The location of
ribosomes in the gradient was monitored by visualizing rRNA isolated from each fraction on agarose gels.
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mRNAs across the gradient, allowing us to normalize for any po-
tential effects of the mTOR inhibitor on mRNA transcription,
processing, or nuclear export.
Using this approach, we determined the extent of polysome
association for three host mRNAs previously shown to require the
eIF4F complex for their efficient translation (27, 28). Figure 6A
shows that the host HSP90 and GNB2L1 transcripts are efficiently
translated in infected cells as determined by their relative abun-
dance in polysome-containing fractions (fractions 11 to 14). Al-
though the rps20 mRNA is less efficiently translated than either of
the above, rps20 transcripts were clearly present in polysomes.
Treating infected cells with Torin1 decreased the association of
each of the host mRNAs with polysomes, with a corresponding
increase in the amount of each mRNA in the monosome-contain-
ing fractions (Fig. 6A). Torin1 decreased the steady-state levels of
the HSP90 and GNB2L1 proteins (Fig. 6B) demonstrating that
changes in polysomes association are reflective of changes in pro-
tein abundance. We also measured the rate of incorporation of
radiolabeled amino acids into nascent HSP90 and GNB2L1 pro-
tein during the final hour of Torin1 treatment. Fewer radiolabeled
amino acids were incorporated into nascent HSP90 or GNB2L1
proteins in the presence of Torin1, confirming that their transla-
tion was inhibited (Fig. 6C). These results show that the degree of
eIF4F disruption achieved with Torin1 is sufficient to inhibit the
translation of eIF4F-dependent mRNAs. We conclude that host
eIF4F-dependent mRNAs continue to require eIF4F for their
translation during HCMV infection.
We next determined the effect of eIF4F disruption on the transla-
tion of viral mRNAs. We found representative viral mRNAs from
each kinetic class associated with polysomes as efficiently in
Torin1 treated cells as in untreated cells (Fig. 7A). The steady-state
levels of each viral protein were minimally affected by Torin1
treatment as determined by Western blotting (Fig. 7B). Similarly,
the rate of nascent protein synthesis for each viral protein was
unaffected by Torin1 treatment (Fig. 7C). A potential caveat of
this approach stems from the fact that HCMV mRNAs are pack-
aged into the tegument of virions. Therefore, the migration of
viral mRNAs in the gradient could reflect their association with
virions rather than polysomes. However, we found that the inclu-
sion of EDTA in lysis buffer, which disrupts polysomes (29) (see
also Fig. S1 in the supplemental material), shifted both the IE1 and
UL99 mRNAs to lighter fractions of the gradient. Together, these
data show that substantial disruption of the eIF4F complex does
not inhibit the recruitment of ribosomes to HCMV mRNAs.
Several potential explanations existed for the differential effect
of eIF4F disruption on host and viral mRNA translation. We con-
sidered the hypothesis that the viral mRNAs examined lacked suf-
ficient 5=UTR structure to require eIF4F activity for their transla-
tion. In vitro studies have shown that mRNAs lacking stable
secondary structure have a minimal requirement for eIF4F for
their translation (30). The 5=UTR for each of the examined viral
mRNAs has previously been mapped. In each case the free energy
constraints of the viral 5=UTRs would predict that eIF4F was
needed for their efficient translation (see Fig. S2A in the supple-
mental material). Another possibility was that HCMV mRNAs are
not capped and therefore would not require the eIF4F complex for
their translation. Surprisingly, we were unable to find any infor-
mation concerning the presence of an m7G mRNA cap on either
the UL44 or UL99 mRNAs. We therefore used tobacco acid pyro-
phosphatase (TAP)-mediated RNA ligation to test for the pres-
ence of an m7G mRNA cap on the viral mRNAs (see Materials and
Methods). We found that polysome-associated mRNAs for both
viral genes were capped and therefore have the potential to inter-
act with eIF4F (see Fig. S2A).
Based on these results, we performed a global analysis of the
FIG 6 eIF4F disruption limits the association of host mRNAs with polysomes.
(A) HFFs were infected and treated as in Fig. 5. At 96 hpi, cytoplasmic extracts
were resolved through sucrose density gradients. The abundance of the indi-
cated mRNAs in each gradient fraction was determined by qRT-PCR. The
percentage of the total RNA in the gradient in each fraction is shown (,
untreated; , Torin1 treated; n  3). (B) Cells were treated as in panel A.
Steady-state protein levels were measured by Western blotting. (n  3). (C)
Cells were treated as in panel A. Nascent proteins were metabolically labeled
during the final 30 min of the assay. Immune complexes specific for the indi-
cated proteins were visualized by autoradiography. The results of a represen-
tative experiment (n  3) are shown in panels B and C.
FIG 7 eIF4F disruption does not affect the association of viral mRNAs with
polysomes late in infection. (A) HFFs were infected and treated as in Fig. 5. The
distribution of viral mRNAs across a sucrose gradient was determined by qRT-
PCR as in Fig. 6A (n  3). (B) Cells were treated as in Fig. 6B. Steady-state
protein levels were measured by Western blotting (n  3). (C) Cells were
treated as in Fig. 6C. Nascent proteins were metabolically labeled during the
final 30 min of the assay. Immune complexes specific for the indicated proteins
were visualized by autoradiography (n  3). The results of a representative
experiment (n  3) are shown in panels B and C.
Role of eIF4F in HCMV mRNA Translation
February 2014 Volume 88 Number 3 jvi.asm.org 1479
effect of eIF4F disruption on the translation of host and viral
mRNAs. For each mRNA we determined the translation effi-
ciency, which is the ratio of mRNA abundance in the polysome
compared to the total RNA sample. We then compared the trans-
lation efficiency for each mRNA in untreated cells and Torin1-
treated cells. In these experiments, we used a custom microarray
containing oligonucleotide probes specific for all annotated
HCMV open reading frames, as well as 44,000 human genes. Table
S1 in the supplemental material lists host mRNAs with statistically
significant changes in their translation efficiency in the presence of
Torin1. We identified more than 340 host mRNAs whose transla-
tion efficiency was decreased by 40% in Torin1-treated cells.
The results of our analysis of host mRNAs were similar to those
described previously (27, 28). For example, we found that Torin1
inhibited the translation of mRNAs encoding ribosomal proteins
(Fig. 8A), which are translated in an eIF4F-dependent manner.
We found that several host mRNAs previously shown to require
eIF4F for their translation during HCMV infection were trans-
lated less efficiently in the presence of Torin1 (31).
In contrast, the relative translation efficiency of HCMV mRNAs was
for the most part similar in untreated and Torin1-treated cells
(Fig. 8B and see Table S2 in the supplemental material). Torin1
treatment resulted in a statistically significant decrease in the
translation of only one viral mRNA (UL17). In addition, the trans-
lation of four viral mRNAs (UL34, UL25, US1, and UL99) showed
a statistically significant increase in translation efficiency in
Torin1-treated cells. Torin1 treatment did not have a significant
impact on the translation of the remaining 98 viral genes mea-
sured. The array data were confirmed by qRT-PCR for several
viral mRNAs (see Fig. S3 in the supplemental material) using
monosome and polysome fractions isolated from two additional
experiments. No signal was obtained from either step when re-
verse transcriptase step was omitted, indicating the absence of
DNA contamination (data not shown). These results further dem-
onstrate that the Torin1 treatment used in these experiments is
sufficient to inhibit the translation of host mRNAs that utilize the
eIF4F complex. However, the translation of HCMV mRNAs as a
group does not correlate with the abundance or activity of the
eIF4F complex.
DISCUSSION
In this study, we measured the requirement for the host eIF4F
translation initiation complex for the translation of host and viral
mRNAs during HCMV infection. Our results demonstrate a dif-
ferential requirement for eIF4F in the translation of host and viral
mRNAs. We found that eIF4F is required at the start of infection
for efficient progression through the viral lytic cycle. However, as
infection progresses, both viral protein synthesis and replication
become increasingly insensitive to inhibition or disruption of the
eIF4F complex. In contrast, host eIF4F-dependent mRNAs con-
tinue to require eIF4F for their translation in infected cells. Our
results therefore reveal a fundamental difference between host and
HCMV mRNAs in their requirement for host translation factors.
We found that inhibiting or depleting the eIF4A subunit of the
eIF4F complex from the start of infection inhibited progression
through the HCMV lytic cycle. Specifically inhibition of eIF4A
from the start of infection prevented viral DNA replication. These
data are consistent with previous studies showing that inhibition
of the mTOR kinase with Torin1 from the start of infection limits
HCMV DNA accumulation and replication. Precisely how eIF4F
contributes to viral DNA replication is currently unclear. Seven
HCMV proteins are required for viral DNA replication in vitro
(32). Perhaps one or more of these viral factors is dependent on
eIF4F activity for their synthesis prior to viral DNA replication.
This is consistent with our finding that pUL44 expression is de-
layed and reduced when eIF4A is depleted or inhibited at the start
of infection despite the efficient expression on an IE protein. Al-
ternatively, eIF4F activity might be required for the expression of
a host protein needed for viral DNA replication or for the expres-
sion of viral DNA replication proteins. Recent studies have shown
that eIF4F is required for the translation of several host metabolic
enzymes (27). As HCMV infection remodels host metabolism (20,
33–36), perhaps the increased eIF4F abundance and activity in
infected cells promotes the expression of metabolic enzymes
needed for virus replication.
Of particular interest is our finding that eIF4A activity is not
required for the efficient translation of viral mRNAs during the


















































































FIG 8 Global analysis of the effect of eIF4F disruption on the translation efficiency of host and viral mRNAs. (A) HFFs were infected and treated as in Fig. 5.
Polysome-associated and total RNA were isolated from infected cells treated with Torin1 or left untreated. The translation efficiency of each mRNA was
calculated by determining the ratio of the mRNA in the polysome and total fractions by microarray analysis. The graph shows the ratio of the translation efficiency
(TE) in Torin1-treated cells to that in untreated cells. (n  3) mRNAs translated as efficiently in both conditions have a value of 1. Values of 	1 indicate that
translation was inhibited in the presence of Torin1. (A) Relative translation efficiency of representative mRNAs encoding ribosomal proteins in Torin1-treated
cells. (B) Relative translation efficiency of HCMV mRNAs in Torin1-treated cells (n  3). The translation efficiencies of both host and viral mRNAs in untreated
and Torin1-treated cells are given in Tables S1 and S2 in the supplemental material.
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mRNAs examined have minimal structure in their 5=UTRs. In this
case, 40S ribosomal subunits would be capable of scanning viral
5=UTRs without a requirement for helicase activity. However, the
5=UTRs of the representative viral mRNAs examined in the pres-
ent study have been defined and are predicted to have sufficient
structure to impede ribosome scanning (see Fig. S2B in the sup-
plemental material), suggesting that a helicase is required for their
translation. While our data demonstrate a minimal requirement
for eIF4A activity, perhaps another RNA helicase is required for
the resolution of secondary structures in viral mRNAs. Human
cells encode 64 potential RNA helicases, and HCMV itself encodes
a putative RNA helicase (37). If indeed an alternative helicase
contributes to viral mRNA translation, our data suggest that this
helicase is directed specifically to viral mRNAs since the total pro-
tein synthesis remains significantly dependent on eIF4A activity in
infected cells.
Perhaps the most surprising finding was that ribosomes effi-
ciently associate with HCMV mRNAs despite significant disrup-
tion of the eIF4F complex. Early in infection expression of the
HCMV immediate-early protein was resistant to eIF4A inhibi-
tion, while later in infection most mRNAs efficiently associated
with ribosomes despite eIF4F disruption. In a stochastic model in
which eIF4F binds to mRNA in a sequence-independent manner,
one would expect that the translation of all mRNAs would be
equally affected by disruption of the eIF4F complex. Our results
demonstrating the differential effects of eIF4F inhibition on host
and viral mRNAs argue against this model. However, if eIF4F
preferentially associated with a subset of mRNAs in a sequence-
specific manner, disruption of the eIF4F complex should prefer-
entially affect the translation of that subset of mRNAs. In fact, two
recent studies found that the eIF4F complex is most important for
the translation of host mRNAs containing a tract of pyrimidines
(TOP) or a pyrimidine-rich motif (PRTE) immediately adjacent
to the 5= mRNA cap (27, 28). Our microarray analysis of host
mRNA translation closely matches the results of these previous
studies. The translation of host mRNAs containing TOP motifs
(e.g., ribosomal mRNAs) was preferentially inhibited by eIF4F
disruption. Analysis of the 5=UTRs of the representative viral
mRNAs studied herein did not reveal TOP or PRTE-like motifs,
which is consistent with a minimal role for the eIF4F complex in
their translation. Furthermore, examination of additional HCMV
mRNAs with defined transcript structure did not reveal the pres-
ence of these motifs (unpublished observations). However, the
5=UTRs for the majority of HCMV mRNAs have not been defined.
A more comprehensive understanding of HCMV message struc-
ture is needed to globally assess a role for cryptic TOP motifs in
HCMV mRNA translation.
Our results raise the question of how ribosomes are recruited
to HCMV mRNAs when eIF4F activity is inhibited. Although
Torin1 treatment resulted in sufficient eIF4F disruption to limit
host mRNA translation, some residual eIF4F complex was still
present. Therefore, one explanation could be that a host or viral
factor preferentially recruits the residual eIF4F complex to HCMV
mRNAs. An example might be found in the herpes simplex virus
(HSV) ICP6 protein, which stimulates eIF4F formation (38). Per-
haps a viral protein specifically recruits any remaining eIF4F to
viral mRNAs. Alternatively, a protein or protein complex ex-
pressed during infection might limit the association of the 4EBP1
translation repressor with viral mRNAs. To this end, the HCMV
UL69 protein (pUL69) binds to m7G mRNA cap and associates
with viral mRNAs. Although infection with wild-type HCMV lim-
its 4EBP1 binding to the mRNA cap, 4EBP1 robustly binds m7G
Sepharose in cells infected with a pUL69 mutant virus (39). Per-
haps pUL69 specifically inhibits 4EBP1 binding to eIF4E-associ-
ated viral mRNAs, resulting in the preferential accumulation of
eIF4F on viral messages. The interaction of pUL69 with poly(A)-
binding protein (PABP) further suggests a role for pUL69 in viral
mRNA translation. In uninfected cells, PABP promotes transla-
tion initiation via its interaction with eIF4F, thereby promoting
the formation of the “closed loop” (40). In addition, PABP is
required for efficient HCMV replication (41). pUL69 could bridge
the association of PABP with the mRNA cap on viral transcripts
when eIF4F is limiting. However, in both of the above scenarios
some mechanism must exist to discriminate between host and
viral messages, since the degree of eIF4F disruption obtained in
our experiments was sufficient to limit the translation of host
eIF4F-dependent mRNAs.
It is also possible that the recruitment of ribosomes to viral
mRNAs does not require the eIF4F complex. Many viruses limit
the abundance of the eIF4F complex while efficiently synthesizing
viral proteins. For example, many RNA viruses encode proteases
that cleave eIF4G and inactivate the eIF4F complex (42). Viruses
that inactivate eIF4F often rely on an alternative suite of transla-
tion initiation factors (43). Host cells also utilize alternative trans-
lation initiation complexes, most notably the cap binding com-
plex (CBC) (44). Like eIF4F, the CBC binds to the m7G cap and
can recruit ribosomes to facilitate mRNA translation. Unlike
eIF4F, the CBC does not require the eIF4E protein and is therefore
insensitive to inhibition by 4EBP1 (45). Perhaps viral mRNAs
utilize the CBC to recruit ribosomes to viral mRNAs when eIF4F
activity is limiting. Equally plausible is the existence of an HCMV-
encoded protein or protein complex that facilitates the recruit-
ment of ribosomes to viral transcripts. For example, the N protein
of bunyavirus is capable of replacing the entire eIF4F complex in
the translation of viral mRNAs (46). If viral proteins contribute to
HCMV mRNA translation, these factors would be excellent can-
didates for novel antiviral therapeutics, since they would specifi-
cally limit viral protein synthesis while leaving host protein syn-
thesis intact. Clearly, additional studies are needed to further
define the complement of viral and/or host factors that govern
HCMV protein synthesis.
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